Research Article, Int J Cardiovasc Res Vol: 4 Issue: 5
Circulating Aldosterone Levels and Disease Severity in Pulmonary Arterial Hypertension [Retrieved]
Zeenat Safdar1*, Aishwarya Thakur1, Supriya Singh1, Yingqun Ji1, Danielle Guffey2, Charles G Minard2 and Mark L Entman3 | |
1Division of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Texas, USA | |
2Dan L Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Texas, USA | |
3Division of Cardiology, Baylor College of Medicine, Texas, USA | |
Corresponding author : Zeenat Safdar, MD Associate Professor of Medicine, Director, Baylor Pulmonary Hypertension Program, Pulmonary-Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, Texas 77030, USA Tel: +713 798 2400; Fax: 713 798 2688 E-mail: safdar@bcm.edu |
|
Received: April 01, 2015 Accepted: May 19, 2015 Published: May 21, 2015 | |
Citation: Safdar Z, Thakur A, Singh S, Ji Y, Guffey D, et al. (2015) Circulating Aldosterone Levels and Disease Severity in Pulmonary Arterial Hypertension. Int J Cardiovasc Res 4:5. doi:10.4172/2324-8602.1000227 |
Abstract
Circulating Aldosterone Levels and Disease Severity in Pulmonary Arterial Hypertension
Objective: It is not known whether aldosterone levels are associated with increased mortality in patients with pulmonary arterial hypertension (PAH). The goal of this study was to determine whether circulating aldosterone levels can predict the severity of (PAH) in terms of hemodynamic characteristics and mortality.
Methods: Patients with stable PAH were prospectively enrolled at the Baylor PH program. The plasma levels of aldosterone and BNP were measured. Clinical, hemodynamic, and outcome data was collected. Mean follow up time from study enrollment to follow up was 39 ± 102 months. Cox proportional hazards model was used to assess time to death.